Please note this presentation will not be recorded
A Global Enteric Multicenter Study (GEMS) identified Cryptosporidium parasites as a leading cause of diarrhoeal morbidity and mortality in children under 5, predominantly in low- and middle-resourced regions. Despite the global health burden caused by this parasite, no effective drugs or vaccines exist for the most vulnerable patients. Therapeutic development has been restricted by our limited understanding of Cryptosporidium biology, driven by a historical lack of laboratory tools to study the parasite. The recent advent of genetic manipulation has revolutionised the field, allowing us to expose the molecular basis of disease and rationally identify therapeutic targets. Using these technologies, we have developed a molecular toolkit (nanobodies to highlight the parasites organelles, genetic highthroughput capabilities based on Cas12a, animals models to improve laboratory capcity) to investigate host-Cryptosporidium interactions. Our new resources have enabled the identification several new proteins that manipulate the host actin cytoskeleton that are essential for parasite survival. We have leveraged this knowledge, in collaboration with Merck Sharpe and Dome (MSD), to develop a new highly potent, gut restricted, anti-Cryptosporidium drug. Using recombinant and phenotypic high-throughput screening, we screened 5000 parasite specific compounds developed by WEHI-MSD, achieving a 7% hit rate with EC50s as low as 20nM. Hits were optimised through medicinal chemistry, improving on-target specificity and intestinal restriction, yielding a lead with picomolar IC50 efficacy with significantly improved clearance in infection models. We show the compound’s target, CpASP4, cleaves a defined motif of newly identified effector proteins to enable their export. This compound marks the beginning of a promising new drug for cryptosporidiosis and provides the field with a new tool compound to dissect host-pathogen interactions.